Byrne Asset Management’s AstraZeneca AZN Stock Holding History

Byrne Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.9K	Hold	147	–	–	0.02%	337
2026 Q1	$29K	Sell	147 -3	-2%	-$578	0.02%	317
2025 Q4	$27.6K	Buy	+150	New	+$26.3K	0.02%	323
2025 Q3	–	Sell	-150	Closed	-$22.7K	–	324
2025 Q2	$21K	Hold	150	–	–	0.01%	326
2025 Q1	$22.1K	Hold	150	–	–	0.02%	330
2024 Q4	$19.7K	Hold	150	–	–	0.01%	294
2024 Q3	$23.4K	Hold	150	–	–	0.02%	277
2024 Q2	$23.5K	Hold	150	–	–	0.02%	268
2024 Q1	$20.3K	Hold	150	–	–	0.01%	296
2023 Q4	$20.2K	Hold	150	–	–	0.02%	289
2023 Q3	$20K	Hold	150	–	–	0.02%	267
2023 Q2	$21K	Sell	150 -176	-54%	-$25.9K	0.01%	316
2023 Q1	$58K	Hold	326	–	–	0.04%	212
2022 Q4	$56.9K	Buy	326 +176	+117%	+$22.1K	0.04%	210
2022 Q3	$16K	Hold	150	–	–	0.01%	318
2022 Q2	$20K	Hold	150	–	–	0.01%	275
2022 Q1	$20K	Hold	150	–	–	0.01%	306
2021 Q4	$17K	Buy	+150	New	+$17.6K	0.01%	309

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Byrne Asset Management's AZN Position: Q2 2026 in Review

Byrne Asset Management held its AstraZeneca (AZN) position steady in Q2 2026 at 147 shares worth $27.9K. The position accounts for 0.02% of the portfolio, ranked #337.

Byrne Asset Management first reported a position in AZN in Q4 2021 and has held it in 18 quarters since. The position peaked at $58K in Q1 2023. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Byrne Asset Management held 147 shares of AstraZeneca worth $27.9K as of Q2 2026.
Byrne Asset Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.02% of Byrne Asset Management's portfolio in Q2 2026, its #337 holding.
Byrne Asset Management first reported a position in AstraZeneca in Q4 2021 and has held it in 18 quarters since.
Byrne Asset Management's AstraZeneca position peaked at $58K in Q1 2023.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.